Download this free whitepaper to learn more
As gene therapy programs scale, downstream processing remains a critical bottleneck. Manual density gradient ultracentrifugation is time-consuming, variable and difficult to scale — limiting throughput and increasing risk in regulated environments.
This white paper explores how a semi-automated purification workflow using the OptiMATE™ Gradient Maker and Optima™ X-Series Ultracentrifuges helps manufacturers reduce variability, shorten run times and achieve consistent, high-resolution separation of full and empty AAV capsids.
What You’ll Learn
- Why downstream processing is the biggest challenge in AAV manufacturing
- How pre-formed gradients can cut ultracentrifuge run times by more than 75%
- Real-world performance data and case study results
- How standardized workflows support scalability and GMP compliance
Download the white paper to learn how advanced purification technologies are redefining efficiency and precision in gene therapy manufacturing.
Offered Free by: Beckman Coulter Life Sciences
See All Resources from: Beckman Coulter Life Sciences
